Anticoagulation with recombinant hirudin and danaparoid XXXX in pediatric @entity1 .

@entity1 @entity882 @entity1372 @entity1031 @entity715
@entity1 receiving heparin are at risk of developing @entity882 ( @entity882 ). Whereas in @entity882 only reversible mild @entity882 occurs within the first days of heparin treatment, @entity882 may lead to potentially life-threatening @entity1031 events. Pediatric @entity1 suffering from @entity882 have been reported in a study on newborns and in a few reports on @entity1 and adolescents. However, @entity715 can be as severe in @entity1 as they are in adults. In the case of @entity882 , the withdrawal of heparin is required and alternative anticoagulation should be started. In contrast to numerous investigations in adult @entity1 , including prospective studies, experience with alternative anticoagulants in pediatric @entity1 is limited. The available data were analyzed according to @entity882 , alternative anticoagulation, and clinical outcome. In conclusion, @entity882 represents a potentially dangerous complication of heparin therapy in pediatric @entity1 also. Alternative anticoagulation applied in pediatric @entity1 mainly included danaparoid @entity1372 and recombinant hirudin. In most @entity1 treated with these anticoagulants, effective anticoagulation and clinical improvement were observed. Because of limited experience, more data are required for optimal management of @entity882 in young @entity1 .
